Real-World Study Quantifies Elevated Autoimmune Risk in US Vitiligo Patients

As oral kinase inhibitors inch closer to clinical use for vitiligo, a newly published retrospective cohort study offers timely real-world context for understanding the baseline safety landscape of the disease itself — independent of treatment. Published in The Journal of Dermatology, the analysis found that patients with vitiligo carry meaningfully higher rates of autoimmune, infectious, and auditory comorbidities compared with matched controls, while also revealing racial and ethnic disparities in disease prevalence and incidence that warrant further attention.¹

Study Design and Population

Using the Optum Market Clarity US Electronic Health Record database, investigators identified 15,047 patients aged 12 years and older with a confirmed vitiligo diagnosis between January 2016 and September 2023, along with 75,231 age-, sex-, and race-matched controls without vitiligo. The vitiligo cohort required either a dermatologist-confirmed diagnosis or 2 separate diagnoses at least 30 days apart by a non-dermatologist clinician. Median age in both groups was 51 years, and 56.3% of patients were women. Incidence rates (IRs) of pre-specified safety events were calculated beginning 30 days post-index date.

Autoimmune Burden

The autoimmune comorbidity profile of patients with vitiligo was notably heavy, both at baseline and during follow-up. Before diagnosis, this cohort showed higher proportions of autoimmune thyroiditis, Hashimoto's thyroiditis, psoriasis, alopecia areata, atopic dermatitis, type 1 diabetes, Graves' disease, systemic lupus erythematosus, and several other immune-mediated conditions compared with controls. Post-diagnosis incidence rates reinforced these trends. Alopecia areata carried one of the starkest contrasts, with an IR of 4.52 per 1,000 patient-years (PY) in the vitiligo cohort versus 0.34 per 1,000 PY in controls. Autoimmune thyroiditis showed a similar pattern (5.90 vs. 1.46 per 1,000 PY), as did systemic sclerosis (0.57 vs. 0.11 per 1,000 PY) and Sjögren's syndrome (1.89 vs. 0.86 per 1,000 PY). These findings are consistent with the known shared autoimmune pathogenesis underlying vitiligo and its frequent comorbidities.²

Infections and the JAK Inhibitor Context

Given that several JAK inhibitors are currently under investigation for systemic vitiligo treatment — including ritlecitinib (Litfulo; Pfizer), upadacitinib (Rinvoq; AbbVie), and povorcitinib (Incyte) — the infection data carry particular clinical relevance. Post-diagnosis IRs for herpes simplex (5.83 vs. 4.75 per 1,000 PY), herpes zoster (5.14 vs. 4.09 per 1,000 PY), and opportunistic infections (2.76 vs. 1.95 per 1,000 PY) were all numerically higher in the vitiligo cohort. The authors note that heavier baseline use of systemic corticosteroids and immunosuppressants in this population may partially account for these differences, but underscore the importance of these findings as a benchmark when interpreting infection signals from forthcoming clinical trial data.

Auditory Findings

The elevated rates of hearing-related outcomes in patients with vitiligo — including hearing loss (13.99 vs. 10.15 per 1,000 PY) and sensorineural hearing loss (8.75 vs. 5.13 per 1,000 PY) — aligned with prior studies suggesting melanocyte involvement in inner ear function may contribute to auditory vulnerability in this population. These findings were present at baseline and persisted through follow-up.

Epidemiology by Race and Ethnicity

Asian patients demonstrated numerically higher vitiligo prevalence (1.19 per 1,000 patients) and incidence (0.19 per 1,000 PY) compared with Black and White patients. Hispanic patients similarly showed higher rates than non-Hispanic populations (prevalence 0.87 vs. 0.51 per 1,000). The investigators note that greater disease visibility on darker skin tones may drive increased health care-seeking behavior in these groups, contributing to higher recorded rates, a hypothesis consistent with prior US and UK data.

Cardiovascular and Psychiatric Events

Contrary to what some prior studies have suggested, IRs for cardiovascular events and psychiatric conditions — including depression, psychiatric diagnoses broadly, and suicidal ideation — were lower in the vitiligo cohort than in controls. The authors offer several explanations for the psychiatric finding, including underreporting of mental health conditions, the health care-seeking nature of the control population, and the older-than-typical age of this cohort, which may reflect patients who have developed coping mechanisms over longer disease courses.

Limitations

The authors acknowledge several important limitations. Ascertainment bias is a concern, given that the vitiligo cohort had substantially more baseline dermatologist visits than controls (mean 1.8 vs. 0.2). Vitiligo subtypes could not be distinguished using ICD codes alone, disease onset timing relative to comorbidities could not be determined, and the EHR database captures only treated patients, limiting generalizability to the broader population.

Clinical Takeaway

This study provides a comprehensive real-world comorbidity and epidemiological profile of patients with vitiligo in the United States at a moment when the treatment landscape is actively evolving. As systemic therapies — particularly oral JAK inhibitors — move closer to potential approval, understanding patients' pre-existing risk burden for autoimmune co-conditions, infections, and auditory complications will be essential for informed benefit-risk assessments and individualized treatment planning.

References

1. Cook K, Elbuluk NM, Adiri R, et al. Risk of safety events in vitiligo patients: a retrospective real-world data study in the US. J Dermatol. Published online April 6, 2026. doi:10.1111/1346-8138.70256
2. Hu Z, Wang T. Beyond skin white spots: Vitiligo and associated comorbidities. Front Med (Lausanne). 2023;10:1072837. Published 2023 Feb 23. doi:10.3389/fmed.2023.1072837